Status: Recruiting
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
A Phase II study of HBI0101 (NXC-201) BCMA-CART in Multiple Myeloma and Light-chain Amyloidosis Patients. The goal of the study is to evaluate the efficacy and safety of HBI0101 CART.
Participants needed: 180
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Polina StepenskyUpdated: May 14, 2025Locations: 1
Eligibility criteria
≥18 years of age at the time of signing informed consent. [+8]
Contraindication to a study treatment/procedure or is anticipated to receive tre... [+19]